A cleaner pharma giant with legal baggage
- North American Pharmaceutical distributed $15 billion in GLP-1 medications during the first quarter of fiscal 2027.
- Oncology and Multispecialty grew 33% in Q1 fiscal 2027 to $14.22 billion.
- McKesson plans to separate its Medical-Surgical Solutions unit, which is rebranding as Wellverse.
- Apollo Funds closed a $1.25 billion investment for a 13% stake in the Wellverse business.
- Opioid litigation remains a large overhang with an estimated liability of $5.7 billion.
Focus is the bet
McKesson is becoming a simpler company. It is a massive drug distributor, a specialty care services owner, and a prescription technology provider. The company is currently separating its medical supply business, now rebranded as Wellverse, so investors can value the pharma and specialty care business more directly.
The bull case is that this shift is working. Oncology and Multispecialty revenue rose 33% in the first quarter of fiscal 2027 to $14.22 billion. That segment includes specialty drug distribution, the U.S. Oncology Network, PRISM Vision, and Core Ventures. Meanwhile, the core drug distribution model remains heavily insulated from drug price decreases, as over 95% of branded drugs are handled on a fee for service basis.
Apollo Funds bought a 13% stake in the Wellverse business for about $1.25 billion. This gives the separation plan credibility and provides a rough value for the unit. If McKesson finishes the split cleanly, the market may pay more attention to the faster growing oncology segments and massive GLP-1 volumes.
The bear case remains simple. The biggest segment is still a thin margin, high volume drug distribution business. McKesson also carries a $5.7 billion estimated opioid related liability. A single large customer accounts for 24% of revenue. The separation plan could also cost more or fail to deliver the promised benefits.
Scale makes the machine work
McKesson sits between drug makers, pharmacies, hospitals, doctors, patients, and governments. It buys, stores, moves, and helps manage medicines across North America and other markets. This scale lowers unit costs and makes the company harder to replace.
Most revenue comes from distributing branded, generic, specialty, and over the counter drugs. The dollar amounts are huge, but margins are small because McKesson is moving products for others. Profit depends on volume, purchasing terms, service fees, and keeping the network running with few mistakes. The model relies heavily on fee for service contracts, protecting the company from falling drug list prices.
The growth push is in specialty care and prescription technology. Oncology, ophthalmology, medication access tools, and patient affordability services are attractive areas. They can provide better margins than basic drug distribution if they grow without adding too much complexity.
Where it breaks is concentration and trust. If a national retail customer changes terms or leaves, revenue drops quickly. If regulators or customers lose confidence in how McKesson handles controlled substances or supply chain duties, the costs can last for years.
What McKesson sells
North American drug distribution
This is the largest business. It distributes branded, generic, specialty, and over the counter drugs in the U.S. and Canada.
Oncology and specialty provider services
This includes specialty drug distribution, PRISM Vision, Core Ventures, and practice management services. First quarter fiscal 2027 revenue grew 33%.
Prescription Technology Solutions
This segment connects patients, pharmacies, providers, and biopharma companies to help with medication access and affordability.
Medical-Surgical Solutions (Wellverse)
This unit distributes medical supplies to non acute care settings. McKesson intends to separate it fully after selling a 13% stake to Apollo Funds.
Biopharma services
McKesson provides logistics and access services for drug makers.
International services
Outside the U.S., McKesson provides drug distribution, specialty pharmacy, and infusion care services.
Revenue mix is still pharma heavy
Segment shares use fiscal 2026 revenue from McKesson's Form 10-K. The largest customer represented 24% of consolidated revenue.
What could break the thesis
Medical-Surgical separation misses the plan
High impact · Medium oddsMcKesson lists a specific risk factor for the planned Wellverse separation. The deal may not complete on the expected timeline, may have tax costs, and may not create the financial benefits management expects.
Opioid costs stay large
High impact · Medium oddsMcKesson estimated its opioid related claims liability at $5.7 billion as of March 31, 2026. This remains a major long term cash claim on the business.
One large customer gains leverage
High impact · Medium oddsThe largest customer accounted for 24% of consolidated revenue. McKesson is exposed to contract renewals, pricing pressure, payment delays, or volume shifts from this single account.
Core distribution margin pressure
Medium impact · High oddsNorth American Pharmaceutical generates massive revenue, but drug distribution is a low margin business. If customers demand better pricing, profit will grow slower than revenue.
Oncology acquisitions fail to scale
Medium impact · Medium oddsThe growth case leans heavily on Oncology and Multispecialty. Fast revenue growth is helpful, but the key question is whether these businesses can earn good margins after integration.
In one breath
What does McKesson actually do?
McKesson is a healthcare middleman. It distributes drugs and medical products, helps pharmacies manage prescriptions, and provides services to specialty care practices.
Why is McKesson separating its Medical-Surgical business?
The goal is to focus on pharmaceuticals, specialty care, and prescription technology. Apollo Funds bought a 13% stake in the unit, now called Wellverse, to help prepare for a full split.
Is McKesson mostly an oncology company now?
No. North American Pharmaceutical is still far larger. However, Oncology and Multispecialty is the faster growing piece, with first quarter fiscal 2027 revenue growing 33%.
What is the biggest risk for McKesson investors?
There are several. The main ones are the $5.7 billion opioid related liability, customer concentration, thin margins in drug distribution, and whether the Wellverse separation works as planned.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Medical Distribution companies
Companies near McKesson Corporation in Finn's Medical Distribution industry ranking.
